Latest revenue
$796.0K
as of 2025-09-30
Latest net income
$-1.2M
as of 2025-09-30
Net margin
-156.6%
as of 2025-09-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ABVC is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $34.5M
- Enterprise value
- $36.2M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 3.10×
- Dividend yield
- 0.0%
- 52-wk high
- $5.48
- 52-wk low
- $0.90
- Beta
- —
- Shares out
- 26.0M
5-year trend
What this company does
ABVC Biopharma is an early-stage botanical drug developer with seven CNS and oncology drug candidates plus an eye-surgery device, all licensed from related parties and mostly in Phase II trials. Revenue currently comes from outlicensing intellectual property and contract drug manufacturing services through its BioKey GMP facility, supplemented by a maitake mushroom dietary supplement line. The company has spent the past year fighting Nasdaq delisting threats over minimum bid price and stockholders' equity shortfalls, regaining compliance on both in May 2025.
Generated from ABVC's filing dated 2026-03-03
Key risks
- Nasdaq listing fragility: Company twice fell below Listing Rule 5550 thresholds in 2025; stockholders' equity was just $723,959 in April 2025.
- Pipeline concentration on early-stage assets: All 7 drugs and 1 device are licensed from related parties, with no Phase III or approved products.
- GMP manufacturing license expired December 2, 2024; renewal still 'in progress,' jeopardizing BioKey's CDMO revenue stream and clinical supply capability.
Generated from ABVC's filing dated 2026-03-03
Profitability
Gross margin
99.9%
201.7%Operating margin
-923.3%
82.9%Net margin
-962.1%
86.1%Return on equity
-71.2%
82.2%Return on assets
-37.5%
42.3%Leverage
Debt / equity
0.90×
82.6%Debt / assets
47.2%
43.6%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | — | — | $-3.6M | -279.1% | — |
Q3 2025 2025-09-30 | $796.0K | +104.5% | $-1.2M | -568.2% | -156.6% |
Q2 2025 2025-06-30 | — | — | $-2.3M | -139.5% | — |
Q1 2025 2025-03-31 | — | — | $-842.1K | +70.3% | — |
Q4 2024 2024-12-31 | $2.0K | — | $-939.8K | — | -47801.7% |
Q3 2024 2024-09-30 | $389.3K | +2350.7% | $-186.6K | +94.4% | -47.9% |
Q2 2024 2024-06-30 | $117.1K | +1817.5% | $-942.3K | +58.4% | -804.4% |
Q1 2024 2024-03-31 | $1.2K | — | $-2.8M | — | -235203.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ABVC — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for ABVC in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns ABVC
Institutional value
$347.6K
Total shares held
358.4K
Distinct holders
5
-10 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 190.6K | $184.9K | — | New |
| 2 | VANGUARD FIDUCIARY TRUST CO | 97.4K | $94.4K | — | New |
| 3 | BlackRock, Inc. | 56.4K | $54.8K | +0 (+0.0%) | No change |
| 4 | DIMENSIONAL FUND ADVISORS LP | 12.2K | $11.9K | — | New |
| 5 | UBS Group AG | 1.8K | $1.7K | -817 (-31.6%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
With Nasdaq's July 7, 2025 bid-price deadline passed, what is your specific plan—reverse split timing, ratio—to avoid delisting?
- 2
Your drug manufacturing license expired December 2, 2024; is BioKey currently producing, and what revenue has been lost during the renewal delay?
- 3
All seven pipeline drugs are licensed from related parties controlled by Dr. Jiang—what royalty obligations and conflicts should investors be quantifying?
Refreshed when ABVC files a new report · last from 2026-03-03
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.